NON RARE IN EUROPE: Macular telangiectasia type 2 Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

2 events

Mar 2025A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Neurotech Pharmaceuticals — PHASE3

TrialACTIVE NOT RECRUITING

Mar 2025

Encelto: FDA approved

treatment of adults with idiopathic macular telangiectasia type 2 (MacTel)

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Encelto

Neurotech Pharmaceuticals, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Encelto

(revakinagene taroretcel-lwey)Orphan drug

Neurotech Pharmaceuticals, Inc.

Approved Mar 2025FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial

1Phase 3

1Total recruiting

Search clinical trials for NON RARE IN EUROPE: Macular telangiectasia type 2 →

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Macular telangiectasia type 2.
Search PubMed for NON RARE IN EUROPE: Macular telangiectasia type 2 →

Browse all NON RARE IN EUROPE: Macular telangiectasia type 2 news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Macular telangiectasia type 2.

View all NON RARE IN EUROPE: Macular telangiectasia type 2 specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰